Dr. Scholten & Schneeweiß GbR
- Address
- Richard-Wagner-Strasse 13-17, 50674 Cologne, Germany
Dr. Scholten & Schneeweiß GbR - HIV Research Center
Dr. Scholten & Schneeweiß GbR is a specialized research facility focusing on innovative therapeutic strategies for HIV-1 infection management. The center demonstrates expertise in evaluating novel antiretroviral treatment regimens and assessing long-term efficacy outcomes in virologically suppressed patients.
- HIV-1 infection treatment optimization and maintenance therapy
- Novel oral antiretroviral regimens and long-acting formulations
- Comparative effectiveness research versus standard of care approaches
The research center's current focus includes investigating weekly oral dosing strategies combining next-generation antiretroviral agents such as islatravir and lenacapavir, with particular emphasis on their efficacy in maintaining viral suppression in people living with HIV. This work contributes to advancing treatment convenience and adherence while ensuring sustained virological control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Gilead Sciences Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gilead Sciences Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. Scholten & Schneeweiß GbR
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of a Weekly Oral Islatravir/Lenacapavir Regimen Versus Standard Antiretroviral Therapy in Virologically Suppressed HIV-1 Patients | Gilead Sciences Inc. | Phase III | Not Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emtricitabine | 2 | Unknown | 2025-01-27 | 2025-01-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.